ORLANDO, Fla./ MIAMI, July 29- Florida authorities on Friday reported the first sign of local Zika transmission in the continental United States, concluding that mosquitoes likely infected four people with the virus that can cause a rare but serious birth defect. "This means Florida has become the first state in the nation to have local transmission of the Zika... » Read More
The last thing anyone checking into a hospital should have to worry about is getting sicker while there. Yet, hospital-acquired infections are the most common complication of hospital care, claiming about 99,000 lives and costing the U.S. healthcare system about $30 billion each year.
Today's six stocks worth watching.
Shares in AstraZeneca rose sharply in London Wednesday after the drug company won a U.S. court ruling to protect a patent for its blockbuster cholesterol drug, Crestor.
Diabetes has become a pandemic of monumental proportion. Not only has it threatened the lives of millions, but it also has added to the massive economic burden of chronic disease.
Amylin Pharmaceuticals , whose stock rose 20 percent over the last month, is encouraged by a recent study that its experimental drug Bydureon is well tolerated by patients suffering from Type 2 diabetes.
While most people living in the United States might think tuberculosis is a disease that no longer affects this country, in reality, between nine and 14 million Americans are infected with the bacteria that cause TB.
It doesn’t strike the kind of terror that cancer or Alzheimer’s disease do. But there’s a killer hiding in plain sight that might wreak even more devastation: diabetes.
In today's world, the process of providing access to affordable healthcare should be easier than it is. Globally, we're all affected by the rising costs of healthcare in the face of an aging population – increasing expenditures for healthcare is a challenge in every country where Teva has a presence.
Every year millions of the world’s poorest people die from curable or preventable infectious diseases or suffer unnecessary ill health because they do not have access to basic health care services, including essential medicines and vaccines. The reasons for this are complex and plentiful....but these problems cannot be an excuse for inaction, writes Andrew Witty, CEO of GlaxoSmithKline.
Just because you're busy running a company, doesn't mean you have to run yourself into the ground. Get proactive—and we don't mean travel more. See a doctor to learn whether high blood pressure, cancer, diabetes and other serious diseases may be waiting down the road.
Sun protection products are one of the most important over-the-counter, consumer health products, yet despite the rising rate of skin cancers many people don't know what to buy.
Growth in the huge weight-loss business has slowed, but players and concepts continue to enter a crowded field, especially the low-cost kind.
In an age when people obsessively track and share the most minute details of their personal lives, more individuals are relying on digital devices to record and monitor their health data.
Advancements in health care over the last two decades has been nothing short of awe-inspiring, but the endless parade of technological upgrades has also produced a nasty side effect—a stratospheric rise in healthcare costs,
The devices speed up surgery and recovery time, while reducing pain and bleeding. The next generation may even take human error out of the equation.
Federal health regulators said Wednesday the first pill designed to boost the female sex drive failed to make a significant impact on libido in two studies.
Johnson & Johnson is expanding a months-old recall of certain over-the-counter medicines due to complaints about a moldy smell that can cause nausea and sickness.
Thousands of researchers presented studies at the recent cancer forum, but none more significant than those for patients with advanced melanoma.
There is no “quick fix” for cancer, no clear spot of light at the end of the tunnel. This cautious realization is that the fight against cancer is going to take more time than we thought.
Sales of a vaccine for late-stage prostate cancer, Dendreon’s Provenge, are expected to reach $1 billion in the first two years, analysts have predicted. This drug, one of several being showcased at the American Society of Clinical Oncologists meeting, represent a trend in which drugs treat a subgroup of cancer sufferers within the larger disease.